Currently Viewing:
Newsroom
Currently Reading
Pfizer Announces Phase 3 Trial for Atopic Dermatitis Treatment
December 15, 2017 – Samantha DiGrande
Majority of Women With Breast Cancer Surgery Did Not Feel Fully Informed of Treatment Options
December 15, 2017 – Jaime Rosenberg
AJMC® in the Press, December 15, 2017
December 15, 2017 – AJMC Staff
What We're Reading: Medicare Lab Testing; CHIP Deadline; AMA Expands Diabetes Efforts
December 15, 2017 – AJMC Staff
5 Key Takeaways From ASH 2017
December 15, 2017 – Surabhi Dangi-Garimella, PhD
This Week in Managed Care: December 15, 2017
December 15, 2017
What We're Reading: Medical Device Tax; Marijuana and Vaping; Birth Control Without Prescriptions
December 14, 2017 – AJMC Staff
Study Finds Breathing Retraining Associated With Quality of Life Improvement for Patients With Asthma
December 14, 2017 – Laura Joszt
Rain and Pain Not Related, Harvard Researchers Say
December 13, 2017 – Allison Inserro

CVS Health's Big Step in the Health Insurance World: A Bid to Buy Aetna

Surabhi Dangi-Garimella, PhD
At more than $200 per share bid, CVS Health is reportedly in negotiations to buy the health insurance giant Aetna.
At more than $200 per share bid, CVS Health is reportedly in negotiations to buy the health insurance giant Aetna. According to The Wall Street Journal, the total deal is worth more than $66 billion.

The merger could mean the 46.7 million Aetna members could access convenient MinuteClinics run by CVS Health in its stores, in addition to the company’s retail pharmacies. It’d also give members the opportunity for improved care coordination.

If the merger is realized, CVS would wield a significant dominance within the healthcare world, being the largest retail pharmacy chain in the United States, a pharmacy benefit manager (PBM), and potentially one of the largest health insurance businesses. However, the 2 companies could face legal roadblocks, considering recent challenges faced by such announcements—a federal judge ruling blocked the Aetna–Humana ($34 billion) and Anthem–Cigna ($54 billion) mergers earlier this year.

"A monopoly of our healthcare system is not good for any American. We are very concerned about CVS Health acquiring Aetna and the adverse impact that this will have on cancer patients," said Ted Okon, MBA, executive director of the Community Oncology Alliance, in an e-mail. "CVS controls the largest PBM, a national chain of pharmacies, a mail order pharmacy, and a medical plan sponsor. As it is, cancer patients experience delays in getting critical therapy, switched treatment without their physicians’ knowledge, and higher medication costs. It will be a disaster if CVS is now allowed to control one of the largest national insurers." Okon worries that the merger will further drive up healthcare costs for average Americans.

For CVS, this deal might also be in preparation for Amazon’s foray into the pharmaceutical business, following rumors last month that the retail giant was talking to mid-size pharmacy benefit managers for contracts.

At market close on Thursday, which was when The Journal posted the news, Aetna shares climbed almost 12% while CVS saw a drop of about 3%.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!